On December 21, Deloitte officially announced the "High-Tech High-Growth | 2023 China Pharmaceutical and Health Tomorrow Star" list. The list recognizes companies in the pharmaceutical and health field with outstanding performance and innovative potential. These companies cover various sub-sectors of pharmaceuticals and health, such as biopharmaceuticals, medical devices, and medical technology. They have demonstrated exceptional innovation and development potential in their respective fields, making them among the most promising and prospective enterprises in the future of the pharmaceutical and health industry.

Beijing CytoNiche Biotechnology Co., Ltd. (hereinafter referred to as CytoNiche Biotech), with its leading position in the field of large-scale 3D cell intelligent manufacturing, rich achievements in technology research and application transformation, as well as broad prospects for business development, has been honored to be listed on the prestigious list!

On December 28, the Deloitte China North Region Life Sciences and Healthcare Audit Team visited CytoNiche Biotech, and Ms. Zheng Qun, Managing Partner of Deloitte China North Region Life Sciences and Healthcare Audit, presented the trophy to CytoNiche Biotech.

The "High-Tech High-Growth" enterprise selection activity by Deloitte originated in Silicon Valley, USA, in 1995 and entered China in 2005. It is held simultaneously every year in dozens of countries worldwide, aiming to actively discover outstanding, uniquely innovative, and thriving science and technology enterprises. Most of the selected enterprises are in their early stages, and many industry leaders have emerged from this list, known as the "cradle of great tech companies." Global well-known technology companies such as Apple, Google, Alibaba, and Tencent were selected on this list during their early growth stages.

The "2023 China Pharmaceutical and Health Tomorrow Star" list is a key project of the "High-Tech High-Growth" selection, attracting widespread attention from the industry. It aims to recognize outstanding enterprises in the pharmaceutical and health sector that are leading and have enormous growth potential, ultimately selecting 50 companies with particularly outstanding comprehensive strength for inclusion in the list.

As a national-level high-tech enterprise and a national-level "Specialized, Refined, Unique, and Innovative (S.R.U.I.) Little Giant" enterprise, CytoNiche Biotech's inclusion in the "China Pharmaceutical and Health Tomorrow Star" list reflects its outstanding innovation exploration capabilities and strong technological breakthrough strength.

In the future, CytoNiche Biotech will continue to build and develop the original 3D cell intelligent manufacturing platform, continuously unleash standardized capabilities, research and development transformation capabilities, stimulate industry innovation vitality, lead technological innovation in the industry, and jointly embark on a new era of industrialized development in the cell industry with industry partners.

[About CytoNiche]

CytoNiche was established in 2018, led by Professor Yanan Du's research team from the School of Medicine at Tsinghua University, with Tsinghua University as a shareholder. The core technology originated from the transformation of scientific achievements at Tsinghua University and was recognized as a leading technology in "Science and Technology Innovation in China" by the China Association for Science and Technology. As a national-level high-tech enterprise, a national-level specialized and new technology "Little Giant" enterprise, a potential unicorn enterprise, it has also received key research and development special support from the Ministry of Science and Technology.

As an expert in high-quality three-dimensional cell manufacturing, CytoNiche provides a one-stop customized solution for cell scale-up based on 3D microcarriers. The company has built an original 3D cell smart manufacturing platform, achieving large-scale, automated, intelligent, and closed-cell drug and derivative production preparation. This helps global customers establish the most advanced cell drug production lines. After pioneering the production process pipeline for "billion-level" stem cells, the company is accelerating towards "hundred billion-level," dedicating efforts to empower the cell and gene therapy industry with 3D cell scale-up smart manufacturing technology to benefit more patients.